Gan & Lee Pharmaceuticals
SSE:603087

Watchlist Manager
Gan & Lee Pharmaceuticals Logo
Gan & Lee Pharmaceuticals
SSE:603087
Watchlist
Price: 44.65 CNY 0.86%
Market Cap: 26.4B CNY
Have any thoughts about
Gan & Lee Pharmaceuticals?
Write Note

Gan & Lee Pharmaceuticals
Non-Reccuring Items

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Gan & Lee Pharmaceuticals
Non-Reccuring Items Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Non-Reccuring Items CAGR 3Y CAGR 5Y CAGR 10Y
Gan & Lee Pharmaceuticals
SSE:603087
Non-Reccuring Items
-ÂĄ12.2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Non-Reccuring Items
-ÂĄ248k
CAGR 3-Years
N/A
CAGR 5-Years
21%
CAGR 10-Years
N/A
Akeso Inc
HKEX:9926
Non-Reccuring Items
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Non-Reccuring Items
-ÂĄ222.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Non-Reccuring Items
-ÂĄ1.2m
CAGR 3-Years
16%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Non-Reccuring Items
-ÂĄ1.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Gan & Lee Pharmaceuticals
Glance View

Market Cap
26.8B CNY
Industry
Biotechnology

Gan & Lee Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of recombinant insulin analogue raw materials and injections. The company is headquartered in Beijing, Beijing and currently employs 3,278 full-time employees. The company went IPO on 2020-06-29. The firm's main products are insulin preparations and insulin dry powder, including Changxiulin recombinant insulin glargine injection and Suxiulin recombinant insulin lispro injection. The company is also involved in the development and sales of a type of insulin pen called Xiulin Pen and the components. The firm provides early-stage franchising services by authorizing other companies to sell its insulin injections. The firm sells its products to both domestic and international markets, including Mexico and the Middle East.

Intrinsic Value
45.32 CNY
Undervaluation 1%
Intrinsic Value
Price

See Also

What is Gan & Lee Pharmaceuticals's Non-Reccuring Items?
Non-Reccuring Items
-12.2m CNY

Based on the financial report for Dec 31, 2023, Gan & Lee Pharmaceuticals's Non-Reccuring Items amounts to -12.2m CNY.

What is Gan & Lee Pharmaceuticals's Non-Reccuring Items growth rate?
Non-Reccuring Items CAGR 1Y
70%

Over the last year, the Non-Reccuring Items growth was 70%.

Back to Top